[{"address1": "11085 Torreyana Road", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 558 0708", "fax": "858 558 0709", "website": "https://www.bioatla.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer that is in Phase II clinical trial. Its products under clinical development include BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer which is in Phase II clinical trial; BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer that is in Phase II clinical trial; and BA3182, a CAB bispecific candidate that is in Phase I clinical trial for the treatment of adenocarcinomas. In addition, the company develops preclinical candidates comprising BA3361, a CAB-Nectin-4-ADC for multiple tumor types; BA3151, a CAB-B7-H4-ADC; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on many solid tumors; CAB-EGFR bispecific programs; and BA3362, a dual CAB bispecific product candidate. BioAtla, Inc. was founded in 2007 and is headquartered in San Diego, California.", "companyOfficers": [{"maxAge": 1, "name": "Dr. Jay M. Short Ph.D.", "age": 65, "title": "Co-Founder, CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2022, "totalPay": 1057809, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard A. Waldron", "age": 69, "title": "Senior VP & CFO", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": 617616, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric L. Sievers M.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 608178, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christian J. Vasquez", "age": 47, "title": "Senior VP of Finance, Corporate Controller & Secretary", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": 408745, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Lisa M. Pelton", "title": "Accounting Manager", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susie  Melody", "title": "Senior Vice President of Human Resources", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Cathy  Chang Ph.D.", "title": "Senior Vice President of Research & Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gerhard  Frey Ph.D.", "title": "Senior Vice President of Technology Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Monica  Sullivan", "title": "Senior Vice President of Intellectual Property & Contracts", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sheri  Lydick", "title": "Chief Commercial Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 8, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.01, "open": 3.09, "dayLow": 3.0111, "dayHigh": 3.67, "regularMarketPreviousClose": 3.01, "regularMarketOpen": 3.09, "regularMarketDayLow": 3.0111, "regularMarketDayHigh": 3.67, "forwardPE": -1.3568628, "volume": 2239181, "regularMarketVolume": 2239181, "averageVolume": 453239, "averageVolume10days": 627460, "averageDailyVolume10Day": 627460, "bid": 3.44, "ask": 3.5, "bidSize": 200, "askSize": 200, "marketCap": 165857872, "fiftyTwoWeekLow": 1.24, "fiftyTwoWeekHigh": 4.068, "fiftyDayAverage": 2.4706, "twoHundredDayAverage": 2.332375, "currency": "USD", "sharesOutstanding": 47935800, "sharesShort": 5105828, "sharesShortPriorMonth": 4728003, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.1065, "heldPercentInsiders": 0.09719, "heldPercentInstitutions": 0.65004, "shortRatio": 10.89, "shortPercentOfFloat": 0.1159, "impliedSharesOutstanding": 47935800, "bookValue": 1.475, "priceToBook": 2.3457627, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -123462000, "trailingEps": -2.65, "forwardEps": -2.55, "52WeekChange": 0.40650403, "SandP52WeekChange": 0.29565787, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "BCAB", "underlyingSymbol": "BCAB", "shortName": "BioAtla, Inc.", "longName": "BioAtla, Inc.", "firstTradeDateEpochUtc": 1608129000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "35fd9bcd-d23c-3ada-beff-01d8b746a34b", "messageBoardId": "finmb_105291463", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.46, "targetHighPrice": 14.0, "targetLowPrice": 10.0, "targetMeanPrice": 12.25, "targetMedianPrice": 12.5, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 111471000, "ebitda": -128549664, "quickRatio": 3.933, "currentRatio": 3.933, "returnOnAssets": -0.46933997, "returnOnEquity": -0.98372, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-28"}]